Although the role of IFN-γ in asthma and allergies is controversial [22], the fact that Δ12-PGJ3 treatment had no effect on IFN-γ (cytokine) production in mice, further suggests that this EPA metabolite may lack adverse responses. This evidence concerns the gene IFNG and allergic disease.